Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Rivermark Medical raised $20 million in a Series D funding round led by Andera Partners to advance its FloStent™ System for treating BPH.
PRIVATEMay 13, 2026•3 months ago
Amount Raised
$20 Million
Round Type
Series D
Investors
Andera Partners
Description
Rivermark Medical secured $20 million in a Series D financing round led by Andera Partners. This funding will accelerate the development of the FloStent™ System, aimed at providing a non-surgical treatment for BPH. The investment will support the ongoing RAPID III clinical trial and regulatory submissions in the U.S. Rivermark Medical is dedicated to transforming BPH treatment through innovative therapies.
Related People
Suggested for you
2 contactsVerified contactsGreg B., Vice President - Market Development hidden
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech